SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2012

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

NOTE 4. SEGMENT INFORMATION

We operate in one business segment: the research, development, and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

Our revenues are currently derived primarily from one licensee for domestic activities, five licensees for international activities, and our domestic sales activities for Altrazeal®.

Revenues per geographic area, along with relative percentages of total revenues, for the year ended December 31, are summarized as follows:

Revenues	2012		%			2011		%
Domestic	$	177,440		48	%	$	22,843		5	%
International		193,154		52	%		461,693		95	%
Total	$	370,594		100	%	$	484,536		100	%

A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total revenues, along with their relative percentage of total revenues, for the year ended December 31 are represented on the following table:

Customers	Product	2012			2011
Customer A	Aphthasol®		13	%		53	%
Customer B	Altrazeal®		32	%		---
Customer C	Altrazeal® Veterinary		14	%		---
Total			59	%		53	%